Baxter presents data validating Gammagard

USA-based firm Baxter presented data on its Gammagard Liquid, that it says support further progress in efforts to make antibody therapy more  convenient for patients with primary immunodeficiency, at the American  Academy of Allergy, Asthma & Immunology annual meeting in Washington DC.  Data from a retrospective analysis of real-world use in the USA showed  current administration uses significantly more immune globulin than  intravenous dosing. The analysis PID patients intravenously administered  immune globulins from Gammagard and 258 subjects on an approved  subcutaneous therapy show the median dose typically given subcutaneously  for those with PID is around 1.39 times the median dose given  intravenously.